文献速递外周动脉疾病

慢性免疫介导炎症性疾病患者因组织缺损的重症肢体缺血行下肢血运重建的结局

Outcomes after Lower Extremity Revascularization for Treatment of Critical Limb Ischemia with Tissue Loss in Patients with Chronic Immune-Mediated Inflammatory Disease.
PubMed 文献 · Ann Vasc Surg · 2018-09-12

回顾性分析3年内同一大学附属医院349例手术(297例患者),比较合并慢性免疫介导炎症性疾病(CIID)与无自身免疫病对照的下肢血运重建结局。CIID与对照组的主要截肢率、血运重建类型及解剖平面无差异,24个月生存率、无截肢间期及再干预需求相似;使用类固醇/抗炎药与改善24个月无截肢间期相关。

要点

  • 合并CIID的重症肢体缺血伴组织缺损患者行下肢血运重建的保肢率与再干预需求与对照相似。
  • 透析、WIFi感染2-3级是24个月无截肢间期的独立预测因素,他汀及类固醇/抗炎药为保护因素。

核心结论

  • 合并CIID的重症肢体缺血伴组织缺损患者可成功接受下肢血运重建,保肢率和再干预需求与无自身免疫病者相似。
  • 使用类固醇/抗炎药物似乎有益。

研究设计与样本

  • 回顾性病历审查,纳入同一大学附属医院3年期间所有因重症肢体缺血伴组织缺损行下肢血运重建的病例。
  • 共349例手术(297例患者):44例(13%)初次截肢,305例(87%)下肢血运重建;血运重建中83%为腔内介入、12%为旁路、5%为杂交。
  • 按有无CIID分组比较,采用卡方检验、Student t检验、Kaplan-Meier法和Cox回归分析。

主要发现

  • CIID与对照组在初次截肢(P=0.11)、血运重建类型(P=0.50)及解剖平面(P=0.43)方面无差异。
  • CIID组与对照组年龄相似(71±14岁 vs 71±13岁;P=0.87),≤1支流出道血管比例(52% vs 47%;P=0.67)、WIFi组织缺损2-3级(66% vs 76%;P=0.09)及WIFi感染2-3级(29% vs 30%;P=0.9)均无差异。
  • CIID组男性比例较低(47% vs 61%;P=0.022),当前吸烟者比例较低(13% vs 27%;P=0.008)。
  • 术后死亡率(P=0.70)、并发症及再手术(P=0.31)在两组间相当。
  • 24个月生存率CIID组与对照组相似(83%±5% vs 86%±3%;P=0.78),无截肢间期(69%±5% vs 61%±4%;P=0.18)及靶肢体血运重建需求(40% vs 53%;P=0.04)亦相似。

临床怎么用

  • 作者认为,合并CIID的重症肢体缺血伴组织缺损患者可成功接受下肢血运重建,保肢率和再干预需求与无自身免疫病者相似。
  • 作者指出,使用类固醇/抗炎药物似乎有益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To evaluate outcomes after lower extremity revascularization for critical limb ischemia with tissue loss in patients with chronic immune-mediated inflammatory disease. METHODS: A retrospective medical record review of all lower extremity revascularization for critical limb ischemia with tissue loss at a university-affiliated hospital over a 3-year period was completed for demographics, comorbidities, lower extremity revascularization indication, angiogram results, complications, mortality, limb salvage, and reintervention. Chronic immune-mediated inflammatory disease (CIID) and control (no autoimmune disease) were compared by chi-squared test, Student's t-test, Kaplan-Meier, and Cox Regression. RESULTS: There were 349 procedures performed (297 patients): (1) 44 (13%) primary amputations and (2) 305 (87%) lower extremity revascularizations, in which 83% were endovascular interventions; 12% was bypass; and 5% was hybrid, in which 40% was infrainguinal and 60% was infrageniculate, 72% Wounds Ischemia Infection Score System (WIFi) tissue loss class 2-3, 35% CIID. No differences were noted between CIID and control for primary amputation (P = 0.11), lower extremity revascularization type (P = 0.50), or lower extremity revascularization anatomic level (P = 0.43). Mean age was 71 + 13 years, and 56% of the patients were of male gender. Those with CIID were of similar age as controls (71 ± 14 vs. 71 ± 13; P = 0.87) and presented with comparable runoff: (1) ≤1 vessel (52% vs. 47%; P = 0.67), (2) WIFi tissue loss classification class 2-3 (66% vs. 76%; P = 0.09), and (3) WIFi infection classification class 2-3 (29% vs. 30%; P = 0.9). They were also less likely to be male (47% vs. 61%; P = 0.022) or current smokers (13% vs. 27%; P = 0.008). Postoperative mortality (P = 0.70) morbidity and reoperation (0.31) were comparable. Twenty-four-month survival was similar for CIID and control (83% ± 5% vs. 86% + 3%; P = 0.78), as was the amputation-free interval (69% ± 5% vs. 61% ± 4%; P = 0.18) and need for target extremity revascularization (40% vs. 53%; P = 0.04). Use of steroids and other anti-inflammatory medications was associated with improved 24-month amputation-free interval (87% ± 9% vs. 63% ± 3%; P = 0. 05). Dialysis (odds ratio: 2.6; 1.5-4.7; P = 0.001), WIFi infection class 2-3 (odds ratio: 2.8; 1.6-4.9; P < 0.001), prerunoff vessel (0-1 vs. 2-3) to the foot (odds ratio: 0.52; 0.37-0.73; P < 0.001), steroids/other anti-inflammatory agents (0.29; 0.06-0.96; P = 0.04), and statins (0.44; 0.25-0.77; P = 0.005) were independent predictors of 24-month amputation-free interval (Cox proportional hazard ratio). CONCLUSIONS: Patients with critical limb ischemia, tissue loss, and concomitant CIID can be successfully treated with lower extremity revascularization with similar limb salvage and need for reintervention. Steroid/anti-inflammatory use appears beneficial.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. O'Brien-Irr MS, Dryjski ML, Dosluoglu HH, et al. Outcomes after Lower Extremity Revascularization for Treatment of Critical Limb Ischemia with Tissue Loss in Patients with Chronic Immune-Mediated Inflammatory Disease. Ann Vasc Surg. 2018. PMID: 30217708. doi:10.1016/j.avsg.2018.07.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。